Medtronic plc (MDT)
| Market Cap | 114.47B |
| Revenue (ttm) | 33.54B |
| Net Income (ttm) | 4.66B |
| Shares Out | 1.28B |
| EPS (ttm) | 3.61 |
| PE Ratio | 24.75 |
| Forward PE | 16.09 |
| Dividend | $2.84 (3.18%) |
| Ex-Dividend Date | Jun 27, 2025 |
| Volume | 6,657,508 |
| Open | 89.61 |
| Previous Close | 90.24 |
| Day's Range | 88.69 - 89.96 |
| 52-Week Range | 79.29 - 96.25 |
| Beta | 0.82 |
| Analysts | Buy |
| Price Target | 98.33 (+10.06%) |
| Earnings Date | Aug 19, 2025 |
About MDT
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair produc... [Read more]
Financial Performance
In 2025, Medtronic's revenue was $33.54 billion, an increase of 3.62% compared to the previous year's $32.36 billion. Earnings were $4.66 billion, an increase of 26.82%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for MDT stock is "Buy." The 12-month stock price target is $98.33, which is an increase of 10.06% from the latest price.
News
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
• Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra's AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to i...
Medtronic: Growth Challenges Persist
Medtronic's decade-long underperformance stems from stagnant revenue growth, declining margins, and inconsistent returns on invested capital, despite a solid dividend history. The Diabetes segment spi...
Medtronic secures CE Mark for MiniMed™ 780G System for insulin-requiring people with diabetes including expanded indications in children as young as two, during pregnancy, and for type 2 diabetes
GALWAY, Ireland , July 21, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in medical technology, today announced CE (Conformité Européenne) Mark in Europe to expand indications of the...
Medtronic announces appointment of MiniMed chief financial officer ahead of intended separation into standalone company
GALWAY, Ireland , July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of ...
Medtronic: Margin Inflection With Diabetes Spin - Key Drivers
Initiate Medtronic with Strong Buy, $161 PT, citing a structural margin inflection from Diabetes spin-off and robust innovation pipeline (120+ approvals). Street underestimates FY27 margin/EPS upside ...
Medtronic: Eyes On The Pipeline And Spin, Shares Still Cheap
I reiterate my buy rating on Medtronic, driven by solid fundamentals and an attractive valuation, despite less upside versus prior estimates. Medtronic continues to deliver steady revenue growth, robu...
Medtronic Board appoints Dr. Joon Lee as a new director
GALWAY, Ireland , June 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory He...
I'm Buying Dividend Aristocrats At Bargain Basement Prices
Now is an opportune time to focus on income stocks like that offer value and stability amid market volatility. I focus on 2 Dividend Aristocrats that are attractively valued while supporting well-cove...
Medtronic: Solid Recent Performance But Better Options Available
Medtronic remains a dependable dividend aristocrat, but its long-term total shareholder returns lag significantly behind peers like Johnson & Johnson and Stryker. Despite a solid 2025 performance, the...
Medtronic Is Separating Its Diabetes Business - Good News For Investors
Medtronic plc MDT announced on May 21 its plans to separate its Diabetes business into a separate, publicly traded company. The separation will occur via a two step transaction – an initial minority I...
Medtronic announces MiniMed as name for planned New Diabetes Company
GALWAY, Ireland , June 12, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced MiniMed as the name for the planned New Diabetes Company following ...
Medtronic Announces Intent To Spin Diabetes Business
Deal OverviewOn May 21, 2025, Medtronic plc (NYSE: MDT; $87.44, Market Capitalization: $112.1 billion), a global leader in medical technology, announced its intent to spin off its Diabetes business in...
Caterpillar To Lead Dividend Increases In June As Lowe's Boosted Payout At End Of May
Dividend growth remains robust for select companies, with Casey's, Oil-Dri, and Matson poised for double-digit increases based on strong earnings and expansion. Caterpillar and Kroger are expected to ...
I'm Buying 2 Must-Own Dividend Bargains
The market continues to chase growth while ignoring once beloved income stocks. Verizon offers a compelling 6.3% dividend yield, robust free cash flow, and trades well below its historical valuation, ...
Medtronic plc (MDT) Bernstein's 41st Strategic Decisions Conference - (Transcript)
Medtronic plc (NYSE:MDT) Bernstein's 41st Strategic Decisions Conference Call May 29, 2025 11:00 AM ET Company Participants Geoff Martha - Chairman and Chief Executive Officer Thierry Pieton - Execut...
No Rolex For Me - I'm Buying Dividends That Pay For Life
I love luxury watches, but buying more to "earn" access to rarer models made me realize how easy it is to waste capital chasing ego-driven goals. Unlike watches, dividend growth stocks offer reliable ...
Medtronic: Diabetes Spin-Off Is Near-Term Catalyst; Rating Upgrade
Upgrading Medtronic to 'Strong Buy' with a $104 fair value, driven by the diabetes business spin-off catalyst. Divesting diabetes enables Medtronic to focus on core cardiac and surgical markets, impro...
Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference
GALWAY, Ireland , May 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it will participate in Bernstein's 41st Strategic Decisions Conferen...
'WIN-WIN': Medtronic CEO explains the reason for diabetes biz spin
Medtronic chairman and CEO Geoff Martha explains why the company is separating the diabetes business on 'The Claman Countdown.' #foxbusiness #usnews #economy #investing #diabetes #health #markets
Medtronic plc (MDT) Q4 2025 Earnings Call Transcript
Medtronic plc (NYSE:MDT) Q4 2025 Earnings Conference Call May 21, 2025 8:00 AM ET Company Participants Ryan Weispfenning - VP and Head of IR Geoff Martha - Chairman and CEO Que Dallara - EVP & Presid...
Medtronic CEO: More companies are spinning off problems, we're spinning off an attractive asset
Geoff Martha, Medtronic CEO, joins 'Money Movers' to discuss the company's spinoff plans, growth strategy and surgical robotics.
Medtronic to split off its fast-growing diabetes business to unlock its value
The new diabetes company will be predominantly business-to-consumer, while Medtronic's model was more business-to-business.
Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase
Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation GALWAY, Ireland , May 21, 2025 /PRNewswire/ -- Medtronic plc ...
Medtronic announces intent to separate Diabetes business
Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; only com...